The spin-off of the University of Barcelona (UB) focused on digital cognitive health Braingaze has closed an investment round of 1.5 million euros. The operation has been led by London-based Ryse Asset Management, and has also included the global venture capital fund Orbit Startups and the Australian firm Artesian.
The startup will use this funding to accelerate the clinical and business development of its diagnostic and therapeutic solutions for cognitive disorders and neurodegenerative diseases, which include Alzheimer's, attention deficit hyperactivity disorder (ADHD) and those linked to the autism spectrum, among others.
Braingaze has promoted innovative technology that is based on the use of video games, patented biomarkers of eye micromovements and deep learning algorithms using Artificial Intelligence. Its diagnostic tools offer a remarkable level of precision and objectivity, while its therapeutic solution improves levels of cognitive function in the neurological field.
The company emerged from the UB to exploit more than two decades of research on the brain circuits of cognitive attention and their link with the ocular sensory systemThe eye-tracking attention training game, played with eye movement, is one of the tools powered by Braingaze, and it has been tested as a therapeutic tool in various clinics with positive results in patients with attention-related disorders. Furthermore, Braingaze's ADHD diagnostic solutions have been used in the Spanish market for years, introduced by pioneering doctors from Barcelona and Madrid.
The company emerged from the UB to exploit more than two decades of research on the brain circuits of cognitive attention and their link to the ocular sensory system. With offices in Barcelona and London, Braingaze focuses on promoting "multi-market business traction growth and the launch of clinical solutions," as well as bringing the business closer to consumers on mobile platforms, according to the company's CEO, Laszlo Bax.
Thus, Braingaze uses digital tools to address "a relevant health and social problem affecting children, adolescents, and adults worldwide," according to Ryse founder and managing partner, Shabir Chowdhary. And digital therapeutics "has the potential to drive treatments equal to or better than pharmaceutical-based treatments," according to Orbit Startups managing general partner, William Bao Bean, who believes that Braingaze will be a game-changer in the diagnosis and treatment of these disorders.